BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

Phase 3

Completed

Conditions: Central Nervous System Diseases

Interventions: Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug: Magnevist

First Posted Date: 2006-11-03

Last Posted Date: 2015-06-08

Lead Sponsor: Bayer

Target Recruit Count: 147

Registration Number: NCT00395460

Locations: 🇨🇳
Fudan University Huashan Hospital, Shanghai, China
🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳
The 1st Affiliated Hosp of the 4th Military Med Uni, Xi'an, Shaanxi, China

and more 1 locations

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939)
Drug: (LMW) Heparin + Vitamin K Antagonist

First Posted Date: 2006-11-03

Last Posted Date: 2014-10-28

Lead Sponsor: Bayer

Target Recruit Count: 543

Registration Number: NCT00395772

Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia

Phase 4

Completed

Conditions: Contraception
Menorrhagia

Interventions: Drug: Levonorgestrel (Mirena, BAY86-5028)
Drug: Cytotec
Drug: Placebo

First Posted Date: 2006-10-27

Last Posted Date: 2014-11-02

Lead Sponsor: Bayer

Target Recruit Count: 204

Registration Number: NCT00393198

Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II

Phase 4

Completed

Conditions: Male Erectile Dysfunction
Sexual Dysfunction

Interventions: Drug: Levitra (Vardenafil, BAY38-9456)
Drug: Placebo

First Posted Date: 2006-09-18

Last Posted Date: 2014-12-24

Lead Sponsor: Bayer

Target Recruit Count: 352

Registration Number: NCT00377793

Dose Escalation Study of SH U04722 in Solid Tumors

Phase 1

Terminated

Conditions: Tumors

Interventions: Drug: SH U04722

First Posted Date: 2006-09-13

Last Posted Date: 2014-12-31

Lead Sponsor: Bayer

Target Recruit Count: 10

Registration Number: NCT00375453

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2006-08-30

Last Posted Date: 2015-10-29

Lead Sponsor: Bayer

Target Recruit Count: 39

Registration Number: NCT00370071

Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.

Phase 3

Completed

Conditions: Healthy

Interventions: Drug: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)

First Posted Date: 2006-08-22

Last Posted Date: 2013-10-11

Lead Sponsor: Bayer

Target Recruit Count: 221

Registration Number: NCT00367276

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.

Phase 3

Completed

Conditions: Prevention
Venous Thromboembolism

Interventions: Drug: Rivaroxaban (BAY59-7939)
Drug: Enoxaparin

First Posted Date: 2006-08-09

Last Posted Date: 2014-10-27

Lead Sponsor: Bayer

Target Recruit Count: 2531

Registration Number: NCT00361894

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Enoxaparin

First Posted Date: 2006-08-09

Last Posted Date: 2014-11-04

Lead Sponsor: Bayer

Target Recruit Count: 3148

Registration Number: NCT00362232

Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

Phase 3

Completed

Conditions: Menorrhagia

Interventions: Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Drug: Medroxyprogesterone acetate

First Posted Date: 2006-08-04

Last Posted Date: 2013-12-09

Lead Sponsor: Bayer

Target Recruit Count: 165

Registration Number: NCT00360490

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy